2-(morpholin-4-yl)-1,7-naphthyridines

US9549932B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Lars Wortmann · Berlin, DE
• Ulrich Lücking · Berlin, DE
• Julien LEFRANC · Berlin, DE
• Hans Briem · Bremen, DE
• Franz VON NUSSBAUM · Val-de-Reuil, FR
• Benjamin Bader · Berlin, DE
• Gerhard Siemeister · Berlin, DE
• Wilhelm Bone · Berlin, DE
• Philip Lienau · Berlin, DE
• Dieter MOOSMAYER · Berlin, DE
• Uwe Eberspächer · Berlin, DE
• Hans SCHICK · Berlin, DE
• Knut Eis · Berlin, DE
• Marcus Koppitz · Berlin, DE
• Antje Margret Wengner · Berlin, DE
• Joanna Grudzinska-Goebel · Berlin, DE

Key dates

• Filing date: May 19, 2016
• Grant date: Jan 24, 2017
• Expiry date: May 19, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6561
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib),to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.